Aβ42 vaccine on the Tg2576 Alzheimer model mice

Mikio Shoji, Yasuo Harigaya, Etsuro Matsubara, Takeshi Kawarabayashi, Tetsuro Murakami, Nobuhiko Oomori, Keiko Sato, Isao Nagano, Koji Abe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In 1999, Schenk et al. [Nature 400 (1999) 173] reported remarkable improvement of Aβ amyloid burden in the transgenic mice brain by immunization with Aβ42 peptides. Soon after, four independent institutes showed the same findings on senile plaque amyloid and improvement of memory disturbance confirming the effect of Aβ vaccine on brain Aβ amyloidosis. In July 2001, Elan Corporation started cooperative Phase I study of AN-1792, synthetic Aβ42 peptide. In September, Phase II study of 375 Alzheimer patients began in Europe. Because of 15 cases of encephalitis in March 2002, this drug trial was suspended. This is serious accident for patients, family and specialists, who hope for a curative therapy for Alzheimer's disease (AD). However, this result provided new insight that brain amyloidosis is reversible. Prompt evaluation of candidate drugs such as anti-Aβ antibody, β-secretase inhibitor or anti-Aβ aggregation should be necessary in the near future.

Original languageEnglish
Pages (from-to)399-403
Number of pages5
JournalInternational Congress Series
Volume1252
Issue numberC
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Vaccines
Amyloidosis
Amyloid
Hope
Brain
Amyloid Precursor Protein Secretases
Drug Evaluation
Amyloid Plaques
Encephalitis
Transgenic Mice
Accidents
Anti-Idiotypic Antibodies
Immunization
Alzheimer Disease
Pharmaceutical Preparations
peptide A42
Therapeutics
AN-1792

Keywords

  • Alzheimer's disease
  • Aβ amyloid
  • Aβ vaccine
  • Efficacy
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shoji, M., Harigaya, Y., Matsubara, E., Kawarabayashi, T., Murakami, T., Oomori, N., ... Abe, K. (2003). Aβ42 vaccine on the Tg2576 Alzheimer model mice. International Congress Series, 1252(C), 399-403. https://doi.org/10.1016/S0531-5131(03)00101-8

Aβ42 vaccine on the Tg2576 Alzheimer model mice. / Shoji, Mikio; Harigaya, Yasuo; Matsubara, Etsuro; Kawarabayashi, Takeshi; Murakami, Tetsuro; Oomori, Nobuhiko; Sato, Keiko; Nagano, Isao; Abe, Koji.

In: International Congress Series, Vol. 1252, No. C, 01.06.2003, p. 399-403.

Research output: Contribution to journalArticle

Shoji, M, Harigaya, Y, Matsubara, E, Kawarabayashi, T, Murakami, T, Oomori, N, Sato, K, Nagano, I & Abe, K 2003, 'Aβ42 vaccine on the Tg2576 Alzheimer model mice', International Congress Series, vol. 1252, no. C, pp. 399-403. https://doi.org/10.1016/S0531-5131(03)00101-8
Shoji M, Harigaya Y, Matsubara E, Kawarabayashi T, Murakami T, Oomori N et al. Aβ42 vaccine on the Tg2576 Alzheimer model mice. International Congress Series. 2003 Jun 1;1252(C):399-403. https://doi.org/10.1016/S0531-5131(03)00101-8
Shoji, Mikio ; Harigaya, Yasuo ; Matsubara, Etsuro ; Kawarabayashi, Takeshi ; Murakami, Tetsuro ; Oomori, Nobuhiko ; Sato, Keiko ; Nagano, Isao ; Abe, Koji. / Aβ42 vaccine on the Tg2576 Alzheimer model mice. In: International Congress Series. 2003 ; Vol. 1252, No. C. pp. 399-403.
@article{2f51a9461f614a45a0985a616add4d63,
title = "Aβ42 vaccine on the Tg2576 Alzheimer model mice",
abstract = "In 1999, Schenk et al. [Nature 400 (1999) 173] reported remarkable improvement of Aβ amyloid burden in the transgenic mice brain by immunization with Aβ42 peptides. Soon after, four independent institutes showed the same findings on senile plaque amyloid and improvement of memory disturbance confirming the effect of Aβ vaccine on brain Aβ amyloidosis. In July 2001, Elan Corporation started cooperative Phase I study of AN-1792, synthetic Aβ42 peptide. In September, Phase II study of 375 Alzheimer patients began in Europe. Because of 15 cases of encephalitis in March 2002, this drug trial was suspended. This is serious accident for patients, family and specialists, who hope for a curative therapy for Alzheimer's disease (AD). However, this result provided new insight that brain amyloidosis is reversible. Prompt evaluation of candidate drugs such as anti-Aβ antibody, β-secretase inhibitor or anti-Aβ aggregation should be necessary in the near future.",
keywords = "Alzheimer's disease, Aβ amyloid, Aβ vaccine, Efficacy, Treatment",
author = "Mikio Shoji and Yasuo Harigaya and Etsuro Matsubara and Takeshi Kawarabayashi and Tetsuro Murakami and Nobuhiko Oomori and Keiko Sato and Isao Nagano and Koji Abe",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0531-5131(03)00101-8",
language = "English",
volume = "1252",
pages = "399--403",
journal = "International Congress Series",
issn = "0531-5131",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Aβ42 vaccine on the Tg2576 Alzheimer model mice

AU - Shoji, Mikio

AU - Harigaya, Yasuo

AU - Matsubara, Etsuro

AU - Kawarabayashi, Takeshi

AU - Murakami, Tetsuro

AU - Oomori, Nobuhiko

AU - Sato, Keiko

AU - Nagano, Isao

AU - Abe, Koji

PY - 2003/6/1

Y1 - 2003/6/1

N2 - In 1999, Schenk et al. [Nature 400 (1999) 173] reported remarkable improvement of Aβ amyloid burden in the transgenic mice brain by immunization with Aβ42 peptides. Soon after, four independent institutes showed the same findings on senile plaque amyloid and improvement of memory disturbance confirming the effect of Aβ vaccine on brain Aβ amyloidosis. In July 2001, Elan Corporation started cooperative Phase I study of AN-1792, synthetic Aβ42 peptide. In September, Phase II study of 375 Alzheimer patients began in Europe. Because of 15 cases of encephalitis in March 2002, this drug trial was suspended. This is serious accident for patients, family and specialists, who hope for a curative therapy for Alzheimer's disease (AD). However, this result provided new insight that brain amyloidosis is reversible. Prompt evaluation of candidate drugs such as anti-Aβ antibody, β-secretase inhibitor or anti-Aβ aggregation should be necessary in the near future.

AB - In 1999, Schenk et al. [Nature 400 (1999) 173] reported remarkable improvement of Aβ amyloid burden in the transgenic mice brain by immunization with Aβ42 peptides. Soon after, four independent institutes showed the same findings on senile plaque amyloid and improvement of memory disturbance confirming the effect of Aβ vaccine on brain Aβ amyloidosis. In July 2001, Elan Corporation started cooperative Phase I study of AN-1792, synthetic Aβ42 peptide. In September, Phase II study of 375 Alzheimer patients began in Europe. Because of 15 cases of encephalitis in March 2002, this drug trial was suspended. This is serious accident for patients, family and specialists, who hope for a curative therapy for Alzheimer's disease (AD). However, this result provided new insight that brain amyloidosis is reversible. Prompt evaluation of candidate drugs such as anti-Aβ antibody, β-secretase inhibitor or anti-Aβ aggregation should be necessary in the near future.

KW - Alzheimer's disease

KW - Aβ amyloid

KW - Aβ vaccine

KW - Efficacy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77953468393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953468393&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(03)00101-8

DO - 10.1016/S0531-5131(03)00101-8

M3 - Article

AN - SCOPUS:77953468393

VL - 1252

SP - 399

EP - 403

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -